Random-forest screening identifies a breast-cancer growth-suppressing role for PCAT19
Source check: Source checked. Not independent scientific confirmation.
Finding: A random-forest survival model helped prioritize lncRNAs from 1054 breast-cancer expression profiles; overlap with differential expression and a separate expression database nominated PCAT19. Knocking down PCAT19 increased proliferation in two breast-cancer cell lines, while overexpression reduced xenograft growth in mice. The work supports a preclinical growth-suppressing role, not a validated treatment. Predicted regulatory networks remain hypotheses, and inconsistent clinical-prognosis wording is not used to establish patient benefit.
Technology: Random forest survival model
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Random-forest survival feature importance selected the top 10% of lncRNAs from 1054 TCGA breast-cancer profiles; intersection with differential expression and external expression evidence helped select PCAT19 for functional experiments.
- Test and result
- Random-forest prioritization was followed by PCAT19 knockdown in two breast-cancer cell lines and overexpression in a mouse xenograft model, supporting an effect on growth. Migration and invasion changes were not statistically significant.
- Limitation / still unknown
- No clinical intervention or treatment benefit is established. The paper contains inconsistent directions in its clinical-prognosis narrative and reports 151 versus 153 tissue cases in different sections; these clinical claims are not represented as validated findings. The proposed ceRNA network remains computational.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.1002/cam4.5872 · https://pmc.ncbi.nlm.nih.gov/articles/PMC10242319/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Exact article-front DOI/title/PMCID and publication date; full primary Methods, Results and limitations. Admission represents the model-prioritized experimental growth result; contradictory clinical prognosis descriptions are explicitly excluded from the claim..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.